Press releases

Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Disea...

Domain Therapeutics to present and participate at major global healthcare conferences, March to June...

Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR...

Domain Therapeutics appoints Sean A. MacDonald as Chief Executive Officer

Domain Therapeutics to participate at premier investor and healthcare conferences

Domain Therapeutics to present latest data on DT-9045, a first-in-class Negative Allosteric Modulat...

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 ...

Domain Therapeutics promotes Stephan Schann as Chief Scientific Officer (CSO)

Domain Therapeutics further strengthens leadership team with appointment of Sean A. MacDonald as Ch...

Domain Therapeutics awarded Hospital-University Research in Health (RHU) SPRINT consortium grant to ...